Virscio

Executive Summary

Virscio is a preclinical contract research organization (CRO) dedicated to accelerating therapeutic innovation through advanced, human-relevant nonhuman primate (NHP) translational models. Founded in 2016 and headquartered in New Haven, Connecticut, the company addresses a critical gap in drug development by improving the predictive accuracy of preclinical testing, thereby reducing the time, cost, and risk of bringing new therapies to market. With a focus on infectious disease and drug delivery, Virscio's specialized services aim to bridge the disconnect between traditional animal models and clinical outcomes. As a private, pre-clinical stage company, Virscio is poised to capture growing demand from biopharma firms seeking more reliable preclinical data to de-risk their pipelines. By leveraging cutting-edge methods and technologies in NHP research, the company differentiates itself in the competitive CRO landscape and offers potential for strategic partnerships and expansions.

Upcoming Catalysts (preview)

• TBDMajor Partnership Announcement with Top 20 Pharma Company60% success
• TBDExpansion of NHP Model Offerings into New Therapeutic Areas75% success
• TBDPublication of Validation Data for Novel NHP Models in Peer-Reviewed Journal80% success